Roelandt F J Schop

Publications (6)25.16 Total impact

• Article: Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.

  Esteban Braggio, Jonathan J Keats, Xavier Leleu, Scott Van Wier, Victor H Jimenez-Zepeda, Riccardo Valdez, Roelandt F J Schop, Tammy Price-Troska, Kimberly Henderson, Antonio Sacco, [......], Suzanne Hayman, S Vincent Rajkumar, John Carpten, Marta Chesi, Michael Barrett, A Keith Stewart, Ahmet Dogan, P Leif Bergsagel, Irene M Ghobrial, Rafael Fonseca
  [show abstract] [hide abstract]
  ABSTRACT: Waldenström's macroglobulinemia (WM) is a distinct clinicobiological entity defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in bone marrow (BM) and IgM paraprotein production. Cytogenetic analyses were historically limited by difficulty in obtaining tumor metaphases, and the genetic basis of the disease remains poorly defined. Here, we performed a comprehensive analysis in 42 WM patients by using a high-resolution, array-based comparative genomic hybridization approach to unravel the genetic mechanisms associated with WM pathogenesis. Overall, 83% of cases have chromosomal abnormalities, with a median of three abnormalities per patient. Gain of 6p was the second most common abnormality (17%), and its presence was always concomitant with 6q loss. A minimal deleted region, including MIRN15A and MIRN16-1, was delineated on 13q14 in 10% of patients. Of interest, we reported biallelic deletions and/or inactivating mutations with uniparental disomy in tumor necrosis factor (TNF) receptor-associated factor 3 and TNFalpha-induced protein 3, two negative regulators of the nuclear factor-kappaB (NF-kappaB) signaling pathway. Furthermore, we confirmed the association between TRAF3 inactivation and increased transcriptional activity of NF-kappaB target genes. Mutational activation of the NF-kappaB pathway, which is normally activated by ligand receptor interactions within the BM microenvironment, highlights its biological importance, and suggests a therapeutic role for inhibitors of NF-kappaB pathway activation in the treatment of WM.
  Cancer Research 05/2009; 69(8):3579-88. · 7.86 Impact Factor
• Article: High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.

  Esteban Braggio, Jonathan J Keats, Xavier Leleu, Scott Van Wier, Victor Hugo Jimenez-Zepeda, Roelandt F J Schop, Marta Chesi, Michael Barrett, Alexander Keith Stewart, Ahmet Dogan, Peter Leif Bergsagel, Irene M Ghobrial, Rafael Fonseca
  [show abstract] [hide abstract]
  ABSTRACT: Cytogenetic analyses have been historically limited in Waldenström's macroglobulinemia (WM) by the difficulty to obtain tumor metaphases. Thus, few recurrent karyotypic abnormalities have been reported and the molecular consequences of these imbalances are largely unknown. We used an array-based comparative genomic hybridization approach to better characterize the recurrent chromosome abnormalities associated with WM pathogenesis and to compare them with the publicly available findings in other B-cell neoplasias. The majority of the recurrent chromosome abnormalities identified in WM were shared with marginal zone lymphomas (MZL), as deletions of 6q23 and 13q14 and gains of 3q13-q28, 6p and 18q. On the other hand, gains of 4q and 8q were recurrently identified in WM but have not been described as being common abnormalities in MZL. The genetic consequences of these specific abnormalities remain elusive and further studies are critical to refine the search and to precise the molecular pathways affected by these abnormalities.
  Clinical Lymphoma & Myeloma 03/2009; 9(1):39-42. · 1.13 Impact Factor
• Article: 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.

  Roelandt F J Schop, Scott A Van Wier, Ruifang Xu, Irene Ghobrial, Gregory J Ahmann, Philip R Greipp, Robert A Kyle, Angela Dispenzieri, Martha Q Lacy, S Vincent Rajkumar, Morie A Gertz, Rafael Fonseca
  [show abstract] [hide abstract]
  ABSTRACT: IgM monoclonal gammopathy of undetermined significance (IgM MGUS) and Waldenström macroglobulinemia (WM) are sometimes clinically difficult to distinguish. In our previous study, deletion of the long arm of chromosome 6 (6q) was found in about half of WM patients. To further clarify the area of minimal deletion at 6q (6q-) and to address the issue of whether 6q- occurs in IgM MGUS, 12 IgM MGUS and 38 WM patients were studied by fluorescence in situ hybridization using probes targeting different chromosomal segments of 6q. No 6q deletions were found in IgM MGUS samples. Of 38 successfully studied WM patients, 21 (55%) showed a deletion of 6q. The area of minimal deletion was between 6q23 and 6q24.3, but the deletion usually encompassed a large fragment of the 6q arm. These results indicate that 6q- can distinguish WM from IgM MGUS and is likely to be a secondary event.
  Cancer Genetics and Cytogenetics 10/2006; 169(2):150-3. · 1.39 Impact Factor
• Article: Genetics and cytogenetics of Waldenstrom's macroglobulinemia.

  Roelandt F J Schop, Rafael Fonseca
  [show abstract] [hide abstract]
  ABSTRACT: Waldenstrom's macroglobulinemia (WM) is a clonal B-cell disorder characterized by the production of a monoclonal paraprotein and lymphoplasmacytic clonal expansion. The genetic basis of this disorder is poorly understood. We have recently found that the genetic makeup of WM cells is different from that commonly reported for multiple myeloma (MM), follicular lymphoma, and B-cell chronic lymphocytic leukemia. Translocations involving the immunoglobulin heavy chain locus (IgH) translocations could not be detected in any case, and a molecular analysis showed that the IgH locus switch mu retained its germline configuration. Aneuploidy was not detected using chromosome enumeration probes. The only recurrent chromosome abnormality found was deletion of 6q21. The lack of legitimate of illegitimate rearrangements at the IgH locus suggests that other mechanisms are involved in the pathogenesis of the disorder. Given the clear evidence of a familial form of WM and the currently presumed genomic stability of the clonal cells, it is likely that a single gene defect may be responsible for disease pathogenesis. Having found deletions of the long arm of chromosome 6 as the only recurrent aberration, we speculate that a gene involved in B-cell maturation or survival at this locus may be inactivated as a cause of WM.
  Seminars in Oncology 05/2003; 30(2):142-5. · 3.50 Impact Factor
• Article: Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions.

  Roelandt F J Schop, W Michael Kuehl, Scott A Van Wier, Gregory J Ahmann, Tammy Price-Troska, Richard J Bailey, Syed M Jalal, Ying Qi, Robert A Kyle, Philip R Greipp, Rafael Fonseca
  [show abstract] [hide abstract]
  ABSTRACT: Lymphoplasmacytic lymphoma (LPL) is characterized by t(9;14)(p13;q32) in 50% of patients who lack paraproteinemia. Waldenström macroglobulinemia (WM), which has an immunoglobulin M (IgM) paraproteinemia, is classified as an LPL. Rare reports have suggested that WM sometimes is associated with 14q23 translocations, deletions of 6q, and t(11;18)(q21;q21). We tested for these abnormalities in the clonal cells of WM patients. We selected patients with clinicopathologic diagnosis of WM (all had IgM levels greater than 1.5 g/dL). Southern blot assay was used to detect legitimate and illegitimate IgH switch rearrangements. In addition to conventional cytogenetic (CC) and multicolor metaphase fluorescence in situ hybridization (M-FISH) analyses, we used interphase FISH to screen for t(9;14)(p13;q32) and other IgH translocations, t(11;18)(q21;q21), and 6q21 deletions. Genomic stability was also assessed using chromosome enumeration probes for chromosomes 7, 9, 11, 12, 15, and 17 in 15 patients. There was no evidence of either legitimate or illegitimate IgH rearrangements by Southern blot assay (n = 12). CC (n = 37), M-FISH (n = 5), and interphase FISH (n = 42) failed to identify IgH or t(11;18) translocations. Although tumor cells from most patients were diploid for the chromosomes studied, deletions of 6q21 were observed in 42% of patients. In contrast to LPL tumors that are not associated with paraproteinemia and that have frequent t(9;14)(p13;q32) translocations, IgH translocations are not found in WM, a form of LPL tumor distinguished by IgM paraproteinemia. However, WM tumor cells, which appear to be diploid or near diploid, often have deletions of 6q21.
  Blood 11/2002; 100(8):2996-3001. · 9.90 Impact Factor
• Article: Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression.

  Roelandt F J Schop, Syed M Jalal, Scott A Van Wier, Gregory J Ahmann, Richard J Bailey, Robert A Kyle, Philip R Greipp, S Vincent Rajkumar, Morie A Gertz, John A Lust, Martha Q Lacy, Angela Dispenzieri, Thomas E Witzig, Rafael Fonseca
  [show abstract] [hide abstract]
  ABSTRACT: Waldenström macroglobulinemia (WM) is a plasma cell dyscrasia characterized by a monoclonal IgM paraproteinemia. Deletions of 17p13.1 and 13q14 are associated with tumor progression and worsened outcome in multiple myeloma (MM), and we thus investigated WM patients for their presence. Patients (n = 40) were required to have a > or = 1.5 g/dl serum IgM paraproteinemia and a monoclonal lymphoplasmacytic infiltrate. We used interphase fluorescence in situ hybridization (FISH) with probes that localized to 17p13.1(LSI p53/CEP 17) and 13q14 (D13S319 and LSI 13 Rb). Of 40 successfully studied patients for 17p13.1(p53) deletions, 6 were abnormal, consistent with hemizygous deletion (15%). Of 37 cases successfully studied for the 13q14 deletions, 6 were also abnormal with one pair of signals deleted (16%). Patients with deletions were more likely to be later in the course of the disease. No obvious clinical associations were noted with the exception that patients with 17p13.1(p53) deletions had a higher percent involvement of clonal cells in the bone marrow. Deletions of these two regions are uncommon in WM, being more common in the late stages of the disease, thus unlikely playing a role in primary disease pathogenesis.
  Cancer Genetics and Cytogenetics 01/2002; 132(1):55-60. · 1.39 Impact Factor